HK1202528A1 - Uracil derivatives as axl and c-met kinase inhibitors axl c-met - Google Patents

Uracil derivatives as axl and c-met kinase inhibitors axl c-met

Info

Publication number
HK1202528A1
HK1202528A1 HK15102863.3A HK15102863A HK1202528A1 HK 1202528 A1 HK1202528 A1 HK 1202528A1 HK 15102863 A HK15102863 A HK 15102863A HK 1202528 A1 HK1202528 A1 HK 1202528A1
Authority
HK
Hong Kong
Prior art keywords
axl
met
kinase inhibitors
uracil derivatives
met kinase
Prior art date
Application number
HK15102863.3A
Other languages
English (en)
Chinese (zh)
Inventor
Reddeppareddy Dandu
Robert L Hudkins
Kurt A Josef
Catherine P Prouty
Rabindranath Tripathy
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1202528A1 publication Critical patent/HK1202528A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102863.3A 2011-11-14 2015-03-20 Uracil derivatives as axl and c-met kinase inhibitors axl c-met HK1202528A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559312P 2011-11-14 2011-11-14
PCT/US2012/065019 WO2013074633A1 (en) 2011-11-14 2012-11-14 Uracil derivatives as axl and c-met kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1202528A1 true HK1202528A1 (en) 2015-10-02

Family

ID=47297443

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102863.3A HK1202528A1 (en) 2011-11-14 2015-03-20 Uracil derivatives as axl and c-met kinase inhibitors axl c-met

Country Status (26)

Country Link
US (5) US9029538B2 (es)
EP (2) EP2780338B1 (es)
JP (2) JP6051434B2 (es)
KR (1) KR20140090678A (es)
CN (2) CN108047201A (es)
AR (1) AR088872A1 (es)
AU (2) AU2012339640B2 (es)
BR (1) BR112014011548A2 (es)
CA (1) CA2852697A1 (es)
DK (1) DK2780338T3 (es)
EA (1) EA023521B1 (es)
ES (1) ES2614824T3 (es)
HK (1) HK1202528A1 (es)
HU (1) HUE033032T2 (es)
IL (3) IL232405A (es)
MX (1) MX342241B (es)
PH (1) PH12016501535A1 (es)
PL (1) PL2780338T3 (es)
PT (1) PT2780338T (es)
SG (2) SG11201402004YA (es)
SI (1) SI2780338T1 (es)
TW (1) TWI562989B (es)
UA (1) UA114900C2 (es)
UY (1) UY34451A (es)
WO (1) WO2013074633A1 (es)
ZA (1) ZA201402940B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033032T2 (hu) 2011-11-14 2017-11-28 Ignyta Inc Uracil-származékok mint AXL és c-MET kináz inhibitorok
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
US20140121126A1 (en) * 2012-10-25 2014-05-01 Memorial Sloan-Kettering Cancer Center Methods of detecting axl and gas6 in cancer patients
TW201542532A (zh) 2013-07-08 2015-11-16 Bayer Cropscience Ag 作為殺蟲劑的六員ｃ－ｎ－鍵結之芳基硫化物及芳基亞碸衍生物
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN105683197B (zh) * 2013-08-02 2019-12-27 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法
EP3066096A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
EP3066098A1 (de) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
CA2929188C (en) 2013-11-20 2022-08-09 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
BR112016012146B1 (pt) 2013-11-27 2022-11-01 Signalchem Lifesciences Corporation Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
WO2015100117A1 (en) * 2013-12-26 2015-07-02 Cephalon, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US10654808B2 (en) * 2015-04-07 2020-05-19 Guangdong Raynovent Biotech Co., Ltd. Tyrosine kinase inhibitor and pharmaceutical composition comprising same
DK3286177T3 (da) * 2015-04-14 2020-06-08 Qurient Co Ltd Quinolinderivater som tam rtk-inhibitorer
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
JP2019527231A (ja) * 2016-08-01 2019-09-26 イグナイタ インコーポレイテッド がんを治療するための組み合わせ
WO2018026877A1 (en) 2016-08-05 2018-02-08 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
US20190224200A1 (en) * 2016-08-24 2019-07-25 Ignyta, Inc. Combinations for the treatment of cancer
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
MX2019008787A (es) 2017-01-26 2019-09-11 Ono Pharmaceutical Co Sal de etano-sulfonato del derivado de quinolina.
CN108623568B (zh) * 2017-03-21 2022-04-19 南京汇诚制药有限公司 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
KR20200088308A (ko) 2017-09-27 2020-07-22 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN107573340B (zh) * 2017-10-23 2020-11-24 江西科技师范大学 2-氨甲酰基-4-芳杂吡啶类化合物的制备及应用
WO2019101178A1 (zh) * 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
WO2019213340A1 (en) * 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
CN110511218A (zh) * 2018-05-21 2019-11-29 中国科学院上海药物研究所 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
WO2019231942A1 (en) * 2018-06-01 2019-12-05 Rigel Pharmaceuticals, Inc. Quinoline derivatives useful as tyrosine kinase inhibitors
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
EP3842425B1 (en) * 2018-08-24 2024-05-22 TransThera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
EP3845527A4 (en) * 2018-08-27 2022-06-08 Beijing Yuezhikangtai Biomedicines Co., Ltd. MULTISUBSTITUTED PYRIDONE DERIVATIVES AND THEIR MEDICAL USE
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US11203587B2 (en) 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN111196814B (zh) * 2018-11-19 2022-12-06 北京赛特明强医药科技有限公司 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN111840299A (zh) * 2019-04-30 2020-10-30 武汉盛云生物医药科技有限责任公司 一种喹啉类化合物在制备治疗癌症药物中的应用
US20220235029A1 (en) * 2019-05-24 2022-07-28 Medshine Discovery Inc. Crystal form of c-met/axl inhibitor
WO2020238802A1 (zh) * 2019-05-24 2020-12-03 南京明德新药研发有限公司 一种c-MET/AXL抑制剂的晶型
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
WO2021062245A1 (en) * 2019-09-26 2021-04-01 Exelixis, Inc. Pyridone compounds and methods of use in the modulation of a protein kinase
EP4045037A4 (en) 2019-10-16 2023-11-15 ChemoCentryx, Inc. HETEROARYL-BIPHENYLAMINES FOR THE TREATMENT OF PD-L1 DISEASES
CN114585359A (zh) 2019-10-16 2022-06-03 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
CN113620873B (zh) * 2020-05-07 2023-12-08 沈阳药科大学 含锌结合基以及喹啉骨架的化合物的制备方法和用途
EP4167991A1 (en) * 2020-06-23 2023-04-26 ChemoCentryx, Inc. Methods of treating cancer using heteroaryl-biphenyl amide derivatives
WO2022055893A1 (en) * 2020-09-08 2022-03-17 Ideaya Biosciences Inc. Pharmaceutical combination and tumor treatment
CN112675170B (zh) * 2021-02-03 2022-02-01 南华大学附属第一医院 V027-0576在制备抗肿瘤药物中的应用
CA3211063A1 (en) * 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
WO2022237843A1 (zh) * 2021-05-12 2022-11-17 微境生物医药科技(上海)有限公司 Axl抑制剂
EP4371978A1 (en) * 2021-07-13 2024-05-22 Nippon Soda Co., Ltd. Method for producing uracil compound
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116693452A (zh) * 2023-05-24 2023-09-05 中山大学 一种喹啉衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
PL204856B1 (pl) 1999-01-22 2010-02-26 Kirin Pharma Kk Pochodne chinoliny lub chinazoliny, jej zastosowanie i kompozycja farmaceutyczna
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
CA2655128A1 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
CA2682733A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
SI2947072T1 (sl) 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
MX2010011224A (es) * 2008-04-16 2011-02-25 Max Planck Ges Zur Fa Rderung Der Wissenschaften E V Derivados de quinoleina como inhibidores de la cinasa axl.
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
CN105461736B (zh) 2011-04-01 2018-06-12 柯瑞斯公司 具有锌结合位的磷脂酰肌醇3-激酶抑制剂
HUE033032T2 (hu) * 2011-11-14 2017-11-28 Ignyta Inc Uracil-származékok mint AXL és c-MET kináz inhibitorok

Also Published As

Publication number Publication date
US20170050949A1 (en) 2017-02-23
DK2780338T3 (en) 2016-12-19
TW201332992A (zh) 2013-08-16
US9120778B2 (en) 2015-09-01
AU2012339640B2 (en) 2017-01-05
AU2012339640A1 (en) 2014-06-05
SG10201510307WA (en) 2016-01-28
IL245658A0 (en) 2016-06-30
IL245658A (en) 2017-06-29
NZ712194A (en) 2016-05-27
NZ624945A (en) 2015-09-25
CN103958497B (zh) 2017-09-01
US9745283B2 (en) 2017-08-29
JP6404299B2 (ja) 2018-10-10
TWI562989B (en) 2016-12-21
CN108047201A (zh) 2018-05-18
MX342241B (es) 2016-09-21
HUE033032T2 (hu) 2017-11-28
JP2014533287A (ja) 2014-12-11
US10017496B2 (en) 2018-07-10
PL2780338T3 (pl) 2017-04-28
SI2780338T1 (sl) 2017-04-26
MX2014005766A (es) 2014-05-30
EP3045453A1 (en) 2016-07-20
UA114900C2 (uk) 2017-08-28
IL232405A0 (en) 2014-07-01
IL232405A (en) 2017-02-28
ZA201402940B (en) 2017-08-30
CA2852697A1 (en) 2013-05-23
AU2017201042A1 (en) 2017-03-09
IL252517A0 (en) 2017-07-31
US20140275077A1 (en) 2014-09-18
BR112014011548A2 (pt) 2017-05-09
US20150210670A1 (en) 2015-07-30
ES2614824T3 (es) 2017-06-02
US9522902B2 (en) 2016-12-20
EP2780338A1 (en) 2014-09-24
CN103958497A (zh) 2014-07-30
SG11201402004YA (en) 2014-05-29
US9029538B2 (en) 2015-05-12
PH12016501535A1 (en) 2017-05-22
EA201490971A1 (ru) 2014-09-30
JP6051434B2 (ja) 2016-12-27
EP2780338B1 (en) 2016-11-09
UY34451A (es) 2013-05-31
KR20140090678A (ko) 2014-07-17
PT2780338T (pt) 2017-02-17
US20150209358A1 (en) 2015-07-30
US20170320853A1 (en) 2017-11-09
AR088872A1 (es) 2014-07-16
EA023521B1 (ru) 2016-06-30
JP2017071612A (ja) 2017-04-13
WO2013074633A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
IL252517A0 (en) Uracil derivatives as axl and c-met kinase inhibitors
HRP20181429T1 (hr) Novi derivati benzimidazola kao inhibitori kinaze
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
HK1199880A1 (en) Benzonitrile derivatives as kinase inhibitors
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
HK1210777A1 (en) Quinazolinone derivatives as parp inhibitors parp
IL232234A0 (en) Inhibitors of aminopyrimidine kinase
IL228928A0 (en) Aminopyrimidine kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201118